Icon
+91 94997 68112
Login Register

Abstral - (0.1,0.2,0.3,0.4,0.6,0.8 mg; Tablet, Sublingual)

Fentanyl Citrate Sentynl
0.1,0.2,0.3,0.4,0.6,0.8 mg; Tablet, Sublingual
Less Than $1000 mn
Less Than 5
Less Than 5
None None
Less Than 5
 None
Indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Yes
******* ** *** ***** ** **** **** ** **** ******* ’***, ’***, *** ’*** *** ******** ** **** **** *** *** ************ *********. ****** *** ****** ** ** ****** **** *** ********** *** ******* **** ******* ********* ** *** ***** ** ***** ******* *** ****** *** ******* ** **** ****.
Abstral Patent 1 Patent 2 Patent 3
******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ *** *** *, **** ******* ******** ** **** *, ****
  1. *** **, **** : ******* ******** ***** ***** *** **** ** **** ******* ’***, ’***, *** ’*** *** ******** ** **** ****.
  2. *** *, **** : ***** ***** * **** ******* ******* ** ******** ***** ** **.
  3. *** **, **** : ***** *** ******* ******* * ********** ********* ** *** ***** ** ***** ******* *** ****** *** ******* ** **** ****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.